GLP-1受体激动剂治疗非酒精性脂肪肝的新进展

R589.3; 非酒精性脂肪性肝病（NAFLD）是在世界范围内最常见的一种肝脏疾病，然而目前尚无特异性的治疗药物。胰升糖素样肽-1受体激动剂（GLP-1Ra）是基于肠促胰素为靶点治疗2型糖尿病的一类新药物。近期，动物和临床研究证实GLP-1Ra类药物能够有效减少肝脏脂肪沉积，减轻脂肪变性，是治疗NAFLD的一类最有希望的药物。本文将GLP-1Ra类药物改善NAFLD基础和临床研究证据及作用机制综述如下。...

Full description

Saved in:
Bibliographic Details
Published in天津医药 Vol. 43; no. 11; pp. 1230 - 1234
Main Author 李春君 于德民
Format Journal Article
LanguageChinese
Published 天津医科大学代谢病医院，天津市内分泌学研究所，卫生部激素与发育重点实验室 邮编300070 2015
Subjects
综述
肠促胰岛素类
胰升糖素样肽-1受体激动剂
胰高血糖素样肽1
脂肪肝
非酒精性脂肪肝
non-alco-holic fatty liver
脂肪肝
肠促胰岛素类
incretins
胰高血糖素样肽1
胰升糖素样肽-1受体激动剂
非酒精性脂肪肝
review
glucogon-like peptide 1 receptor agonist
glucagon-like peptide 1
fatty liver
综述
Online AccessGet full text
ISSN0253-9896
DOI10.11958/j.issn.0253-9896.2015.11.004

Cover

More Information
Summary:R589.3; 非酒精性脂肪性肝病（NAFLD）是在世界范围内最常见的一种肝脏疾病，然而目前尚无特异性的治疗药物。胰升糖素样肽-1受体激动剂（GLP-1Ra）是基于肠促胰素为靶点治疗2型糖尿病的一类新药物。近期，动物和临床研究证实GLP-1Ra类药物能够有效减少肝脏脂肪沉积，减轻脂肪变性，是治疗NAFLD的一类最有希望的药物。本文将GLP-1Ra类药物改善NAFLD基础和临床研究证据及作用机制综述如下。
Bibliography:Non-alcoholic fatty liver disease （NAFLD） is one of the most common diseases across the world, but there is still no specific treatment for NAFLD. Glucogon-like peptide 1 receptor agonist （GLP-1Ra） is a novel drug for the treatment of type 2 diabetes, based on incretin hormone target. Animal and clinical studies have demonstrated that GLP-1Ra can effec？tively reduce fat deposit in liver and attenuate hepatic steatosis. Therefore, GLP-1Ra is a promising therapeutic approachagainst NAFLD. In this review, we provided an overview of the clinical and basic research evidences and mechanisms in re？lieving NAFLD.
LI Chunjun, YU Demin （Metabolic Diseases Hospital ＆ Tianjin Institute of Endocrinology, Tianjin Medical University/Ministry of Health Key Laboratory of Hormones and Development, Tianjin 300070, China）
glucagon-like peptide 1; incretins; fatty liver; review; glucogon-like peptide 1 receptor agonist; non-alco-holic fatty liver
12-1116/R
ISSN:0253-9896
DOI:10.11958/j.issn.0253-9896.2015.11.004